<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">32683565</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>01</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>08</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1573-7217</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>183</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Sep</Month>
            </PubDate>
          </JournalIssue>
          <Title>Breast cancer research and treatment</Title>
          <ISOAbbreviation>Breast Cancer Res Treat</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18).</ArticleTitle>
        <Pagination>
          <StartPage>419</StartPage>
          <EndPage>428</EndPage>
          <MedlinePgn>419-428</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-020-05755-7</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Palbociclib is a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, approved in combination with endocrine therapy for the treatment of women and men with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2- ABC). In the phase 2, open-label, PALOMA-1 trial, palbociclib plus letrozole significantly prolonged progression-free survival (PFS) versus letrozole alone (hazard ratio, 0.488; 95% CI 0.319‒0.748; P = 0.0004; median PFS, 20.2 vs 10.2 months, respectively) in postmenopausal women with estrogen receptor-positive (ER+)/HER2- ABC. Here, we present the final overall survival (OS) and updated safety results.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Postmenopausal women with ER+/HER2- ABC were randomized 1:1 to receive either palbociclib (125 mg/day, 3/1 schedule) plus letrozole (2.5 mg/day, continuous) or letrozole alone (2.5 mg/day, continuous). The primary endpoint was investigator-assessed PFS; secondary endpoints included OS and safety.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 165 patients were randomized. At the data cutoff date of December 30, 2016 (median duration of follow-up, 64.7 months), the stratified hazard ratio for OS was 0.897 (95% CI 0.623-1.294; P = 0.281); median OS in the palbociclib plus letrozole and letrozole alone arms was 37.5 and 34.5 months, respectively. The median time from randomization to first subsequent chemotherapy use was longer with palbociclib plus letrozole than letrozole alone (26.7 and 17.7 months, respectively). The most frequently reported adverse event in the palbociclib plus letrozole arm was neutropenia (any grade, 75%; grade 3 or 4, 59%).</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Palbociclib plus letrozole treatment led to a numerical but not statistically significant improvement in median OS. Pfizer Inc (NCT00721409).</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Finn</LastName>
            <ForeName>Richard S</ForeName>
            <Initials>RS</Initials>
            <Identifier Source="ORCID">0000-0003-2494-2126</Identifier>
            <AffiliationInfo>
              <Affiliation>David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, USA. RFinn@mednet.ucla.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Boer</LastName>
            <ForeName>Katalin</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Onkologia, Szent Margit Korhaz, Budapest, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bondarenko</LastName>
            <ForeName>Igor</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Dnipropetrovsk State Medical Academy, Dnipropetrovsk, Ukraine.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Patel</LastName>
            <ForeName>Ravindranath</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>Comprehensive Blood and Cancer Center, Bakersfield, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pinter</LastName>
            <ForeName>Tamas</ForeName>
            <Initials>T</Initials>
            <AffiliationInfo>
              <Affiliation>Petz Aladar Megyei Oktato Korhaz, Gyor, Hungary.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Schmidt</LastName>
            <ForeName>Marcus</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, University Medical Center Mainz, Mainz, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shparyk</LastName>
            <ForeName>Yaroslav V</ForeName>
            <Initials>YV</Initials>
            <AffiliationInfo>
              <Affiliation>Lviv State Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thummala</LastName>
            <ForeName>Anu</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Voitko</LastName>
            <ForeName>Nataliia</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Kyiv City Clinical Oncology Center, Kyiv, Ukraine.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Bananis</LastName>
            <ForeName>Eustratios</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>Pfizer Inc, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McRoy</LastName>
            <ForeName>Lynn</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Pfizer Inc, New York, NY, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wilner</LastName>
            <ForeName>Keith</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Pfizer Inc, San Diego, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Huang</LastName>
            <ForeName>Xin</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Pfizer Inc, San Diego, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kim</LastName>
            <ForeName>Sindy</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Pfizer Inc, San Diego, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Slamon</LastName>
            <ForeName>Dennis J</ForeName>
            <Initials>DJ</Initials>
            <AffiliationInfo>
              <Affiliation>David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ettl</LastName>
            <ForeName>Johannes</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Obstetrics and Gynecology, Klinikum Rechts Der Isar, Technische Universität München, München, Germany.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT00721409</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType>
          <PublicationType UI="D003160">Comparative Study</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016448">Multicenter Study</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>07</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Breast Cancer Res Treat</MedlineTA>
        <NlmUniqueID>8111104</NlmUniqueID>
        <ISSNLinking>0167-6806</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C506487">ESR1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047628">Estrogen Receptor alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D010879">Piperazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011725">Pyridines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>7LKK855W8I</RegistryNumber>
          <NameOfSubstance UI="D000077289">Letrozole</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="C508053">ERBB2 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D018719">Receptor, ErbB-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>G9ZF61LE7G</RegistryNumber>
          <NameOfSubstance UI="C500026">palbociclib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047628" MajorTopicYN="N">Estrogen Receptor alpha</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077289" MajorTopicYN="N">Letrozole</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017698" MajorTopicYN="Y">Postmenopause</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011725" MajorTopicYN="N">Pyridines</DescriptorName>
          <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018719" MajorTopicYN="N">Receptor, ErbB-2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Advanced breast cancer</Keyword>
        <Keyword MajorTopicYN="N">ER+/HER2−</Keyword>
        <Keyword MajorTopicYN="N">Letrozole</Keyword>
        <Keyword MajorTopicYN="N">Overall survival</Keyword>
        <Keyword MajorTopicYN="N">Palbociclib</Keyword>
      </KeywordList>
      <CoiStatement>R.S. Finn has received consulting fees from Pfizer Inc, AstraZeneca, Bayer, Novartis, Bristol-Myers Squibb, Eisai, Eli Lilly, Merck, and Roche, as well as other research funding from Pfizer Inc and honoraria from Bayer, Pfizer Inc, Bristol-Myers Squibb, Novartis, Eisai, and Eli Lilly. K. Boer has received consulting fees from Pfizer Inc, Novartis, Eli Lilly, and Roche and served on speakers’ bureaus for Pfizer Inc, Novartis, Eli Lilly, AstraZeneca, and Roche. I. Bondarenko, Y. Shparyk, A. Thummala, and N. Voitko have nothing to report. R. Patel is a stockholder of Novartis. J. Ettl received consulting fees from Eli Lilly, Novartis, Pfizer Inc, Roche, and Eisai; performed contracted research for Celgene; and received honoraria and travel support from Celgene, Eli Lilly, Novartis, Pfizer Inc, Roche, and Teva. T. Pinter has received consulting fees from Amgen and Pfizer Inc and served on speakers’ bureaus for Roche, Bayer, Amgen, and Pfizer Inc. M. Schmidt has received honoraria and consulting fees from AstraZeneca, Celgene, Eisai, Eli Lilly, Myelo Therapeutics, Novartis, Pantarhei Oncology, Roche, Pfizer Inc, and Pierre Fabre; has received travel reimbursement from BioNTech, Pfizer Inc, and Roche; and has patents pending with Sividon. D.J. Slamon reports consultant/advisory roles for Pfizer Inc, Eli Lilly, and Novartis; stock ownership in Pfizer Inc; and research funding from Pfizer Inc and Novartis. E. Bananis, L. McRoy, K. Wilner, X. Huang, and S. Kim are employees and stockholders of Pfizer Inc.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>3</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>6</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>1</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">32683565</ArticleId>
        <ArticleId IdType="pmc">PMC7383036</ArticleId>
        <ArticleId IdType="doi">10.1007/s10549-020-05755-7</ArticleId>
        <ArticleId IdType="pii">10.1007/s10549-020-05755-7</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi: 10.3322/caac.21492.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3322/caac.21492</ArticleId>
            <ArticleId IdType="pubmed">30207593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>American Cancer Society (2017) Breast cancer facts &amp; figures 2017–2018. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/breast-cancer-facts-and-figures/breast-cancer-facts-and-figures-2017-2018.pdf. Accessed 27 Aug 2019</Citation>
        </Reference>
        <Reference>
          <Citation>Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, Johnston SR, Korde LA, Khatcheressian JL, Mehta RS, Muss HB, Burstein HJ. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline. J Clin Oncol. 2016;34:3069–3103. doi: 10.1200/JCO.2016.67.1487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2016.67.1487</ArticleId>
            <ArticleId IdType="pubmed">27217461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnston SJ, Cheung K-L. Endocrine therapy for breast cancer: a model of hormonal manipulation. Oncol Ther. 2018;6:141–156. doi: 10.1007/s40487-018-0062-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40487-018-0062-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>National Comprehensive Cancer Network (2019) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Breast Cancer Version 1.2019. https://www.nccn.org/professionals/physician_gls/default.aspx. Accessed 21 Feb 2020</Citation>
        </Reference>
        <Reference>
          <Citation>Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, Toogood PL. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004;3:1427–1438.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15542782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, Los G, Slamon DJ. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77. doi: 10.1186/bcr2419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/bcr2419</ArticleId>
            <ArticleId IdType="pmc">PMC2790859</ArticleId>
            <ArticleId IdType="pubmed">19874578</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015;16:25–35. doi: 10.1016/S1470-2045(14)71159-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(14)71159-3</ArticleId>
            <ArticleId IdType="pubmed">25524798</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rugo HS, Finn RS, Dieras V, Ettl J, Lipatov O, Joy AA, Harbeck N, Castrellon A, Iyer S, Lu DR, Mori A, Gauthier ER, Bartlett CH, Gelmon KA, Slamon DJ. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174:719–729. doi: 10.1007/s10549-018-05125-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10549-018-05125-4</ArticleId>
            <ArticleId IdType="pmc">PMC6438948</ArticleId>
            <ArticleId IdType="pubmed">30632023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Andre F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018;379:1926–1936. doi: 10.1056/NEJMoa1810527.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1810527</ArticleId>
            <ArticleId IdType="pubmed">30345905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ibrance® (palbociclib) (2018) Summary of product characteristics. Pfizer Limited, Sandwich, Kent, UK</Citation>
        </Reference>
        <Reference>
          <Citation>Broglio KR, Berry DA. Detecting an overall survival benefit that is derived from progression-free survival. J Natl Cancer Inst. 2009;101:1642–1649. doi: 10.1093/jnci/djp369.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djp369</ArticleId>
            <ArticleId IdType="pmc">PMC4137232</ArticleId>
            <ArticleId IdType="pubmed">19903805</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gupta S, Zhang J, Jerusalem G. The association of chemotherapy versus hormonal therapy and health outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer: experience from the patient perspective. Expert Rev Pharmacoecon Outcomes Res. 2014;14:929–940. doi: 10.1586/14737167.2014.949243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1586/14737167.2014.949243</ArticleId>
            <ArticleId IdType="pubmed">25130198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Partridge AH, Burstein HJ. Winer EP (2001) Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. 2001;30:135–142. doi: 10.1093/oxfordjournals.jncimonographs.a003451.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/oxfordjournals.jncimonographs.a003451</ArticleId>
            <ArticleId IdType="pubmed">11773307</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwapisz D. Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies. Breast Cancer. 2018;25:506–516. doi: 10.1007/s12282-018-0864-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12282-018-0864-6</ArticleId>
            <ArticleId IdType="pubmed">29700711</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martin M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Sondhi M, Wang Y, Chakravartty A, Rodriguez-Lorenc K, Taran T, Jerusalem G. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382:514–524. doi: 10.1056/NEJMoa1911149.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1911149</ArticleId>
            <ArticleId IdType="pubmed">31826360</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sledge GW, Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Conte P, Lu Y, Barriga S, Hurt K, Frenzel M, Johnston S, Llombart-Cussac A. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6:116–124. doi: 10.1001/jamaoncol.2019.4782.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaoncol.2019.4782</ArticleId>
            <ArticleId IdType="pmc">PMC6777264</ArticleId>
            <ArticleId IdType="pubmed">31563959</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva-Vazquez R, Jung KH, Chakravartty A, Hughes G, Gounaris I, Rodriguez-Lorenc K, Taran T, Hurvitz S, Tripathy D. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019;381:307–316. doi: 10.1056/NEJMoa1903765.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1903765</ArticleId>
            <ArticleId IdType="pubmed">31166679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Dieras V, Slamon DJ. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–1936. doi: 10.1056/NEJMoa1607303.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1607303</ArticleId>
            <ArticleId IdType="pubmed">27959613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M, PALOMA3 Study Group  Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373:209–219. doi: 10.1056/NEJMoa1505270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1505270</ArticleId>
            <ArticleId IdType="pubmed">26030518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martin M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465–2472. doi: 10.1200/JCO.2018.78.9909.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2018.78.9909</ArticleId>
            <ArticleId IdType="pubmed">29860922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904–915. doi: 10.1016/S1470-2045(18)30292-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(18)30292-4</ArticleId>
            <ArticleId IdType="pubmed">29804902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, Andre F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016;375:1738–1748. doi: 10.1056/NEJMoa1609709.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1609709</ArticleId>
            <ArticleId IdType="pubmed">27717303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sledge GW, Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875–2884. doi: 10.1200/JCO.2017.73.7585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.73.7585</ArticleId>
            <ArticleId IdType="pubmed">28580882</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Tredan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638–3646. doi: 10.1200/JCO.2017.75.6155.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1200/JCO.2017.75.6155</ArticleId>
            <ArticleId IdType="pubmed">28968163</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Diéras V, Rugo HS, Schnell P, Gelmon K, Cristofanilli M, Loi S, Colleoni M, Lu DR, Mori A, Gauthier E, Huang Bartlett C, Slamon DJ, Turner NC, Finn RS. Long-term pooled safety analysis of palbociclib in combination with endocrine therapy for HR+/HER2- advanced breast cancer. J Natl Cancer Inst. 2018;111:419–430. doi: 10.1093/jnci/djy109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jnci/djy109</ArticleId>
            <ArticleId IdType="pmc">PMC6449170</ArticleId>
            <ArticleId IdType="pubmed">30032196</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
